

IN THE CLAIMS

Claims 1-16 (cancelled)

D¹ 17(currently amended). A method of treating or preventing the rejection of transplanted organs, tissues or cells which comprises administering to a subject in need thereof a chemokine receptor antagonist for the RANTS receptors and a cyclosporin.

18(previously added). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered simultaneously.

19(previously added). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered sequentially or separately.

D² 20(currently amended). The method according to claim 17, wherein the chemokine receptor antagonist is ~~an amine-~~ terminally a truncated chemokine RANTES.

21(previously added). The method according to claim 17, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

22(previously added). The method according to claim 17, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 23(cancelled)

24(previously amended). The method according to claim 17, wherein the cyclosporin is cyclosporin A.

25(previously added). The method according to claim 24, wherein the chemokine receptor antagonist is Met-RANTES.

26(previously added). The method according to claim 25, wherein the rejection treated or prevented is renal allograft transplantation rejection.

D³ 27(currently amended). The method according to claim 24, wherein the chemokine receptor antagonist is ~~an amino-terminally~~ a truncated chemokine RANTES or an amino-terminally extended RANTES.

Claim 28(missing/never added)

29(previously added). The method according to claim 17, wherein the rejection treated or prevented is renal allograft transplantation rejection.

30(currently amended). A pharmaceutical composition comprising at least one ~~pharmaceutical~~ pharmaceutically acceptable excipient and the combination of a chemokine receptor antagonist for the RANTES receptors and a cyclosporin.

4
31(currently amended). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is ~~an amino-terminally~~ a truncated ~~chemokine~~ RANTES.

32(previously added). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

33(previously added). The pharmaceutical according to claim 30, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 34(cancelled)

35(previously added). The pharmaceutical composition according to claim 30, wherein the cyclosporin is cyclosporin A.

36(previously added). The pharmaceutical composition according to claim 35, wherein the chemokine receptor antagonist is Met-RANTES.

37 (currently amended). The pharmaceutical composition according to claim 34, wherein the chemokine receptor antagonist is ⁵~~an amino-terminally~~ a truncated chemokine RANTES or an amino-terminally extended RANTES.